GlassScriptPhysician profile
Jill S Olek
NPI 1154632685
$7,972.23
in general payments reported to CMS, 2019-2025
44 companies · $1,116 in 2025
The $1,116 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $766 · 2021: $819 · 2022: $1,203 · 2023: $1,726 · 2024: $1,560 · 2025: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,402.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $969.30 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $729.93 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.65 | 2019-2025 | Jardiance, Ofev |
| Amgen INC. | $495.27 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $400.71 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $388.93 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $388.08 | 2019-2025 | Airsupra, Breztri, Evusheld |
| Abbvie INC. | $374.98 | 2020-2023 | |
| Dexcom, INC. | $351.90 | 2023-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $350.14 | 2019-2023 | Xarelto |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $326.04 | 2020-2025 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $263.01 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $236.85 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $192.91 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $189.72 | 2022-2025 | Ingrezza |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Olek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.